24.10.2017 22:45:00
|
Lifshitz & Miller LLP Announces Investigation of Antares Pharma, Inc., CenturyLink, Inc., CytRx Corporation, Dentsply Sirona, Inc., Dr. Reddy's Laboratories Limited, J.Jill, Inc., and Navient...
NEW YORK, Oct. 24, 2017 /PRNewswire/ --
Antares Pharma, Inc. (ATRS)
Lifshitz & Miller announces an investigation on behalf of ATRS investors concerning whether ATRS issued false and misleading statements about its lead product XYOSTED.
If you are an ATRS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
CenturyLink, Inc. (CTL)
Lifshitz & Miller announces an investigation on behalf of CTL investors concerning whether CTL issued false and misleading statements and/or failed to disclose that its policies allowed CTL employees to add services or lines to accounts without customer permission, resulting in millions of unauthorized charges to customers.
If you are a CTL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
CytRx Corporation (CYTR)
Lifshitz & Miller announces an investigation on behalf of CYTR investors concerning whether CYTR issued false and misleading statements about its phase 3 clinical trial of aldoxorubicin. Specifically, on August 14, 2017, the U.S. District Court for the Central District of California denied, in part, CYTR's motion to dismiss a putative class action against CYTR, among others.
If you are a CYTR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Dentsply Sirona, Inc. (XRAY)
Lifshitz & Miller announces an investigation on behalf of XRAY investors after XRAY announced the abrupt resignations of its CEP, COO and Executive Chairman on October 2, 2017.
If you are an XRAY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Dr. Reddy's Laboratories Limited (RDY)
Lifshitz & Miller announces an investigation on behalf of RDY investors concerning whether RDY lacked an effective corporate quality system after RDY received a warning letter from the FDA.
If you are an RDY investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
J.Jill, Inc. (JILL)
Lifshitz & Miller announces an investigation on behalf of JILL investors concerning whether JILL issued false and misleading statements about its purportedly unique sales and marketing approach to insulate JILL from adverse trends affecting the retail industry.
If you are a JILL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Navient Corporation (NAVI)
Lifshitz & Miller announces an investigation on behalf of NAVI investors concerning whether NAVI had adequate internal controls to prevent alleged accounting violations and misconduct in servicing student loans.
If you are a NAVI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING. © 2017 Lifshitz & Miller LLP. The law firm responsible for this advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz & Miller LLP
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@jlclasslaw.com
SOURCE Lifshitz & Miller Law Firm
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu DENTSPLY SIRONA Incmehr Nachrichten
20.11.24 |
NASDAQ Composite Index-Papier DENTSPLY SIRONA-Aktie: So viel Verlust hätte ein DENTSPLY SIRONA-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
13.11.24 |
NASDAQ Composite Index-Titel DENTSPLY SIRONA-Aktie: So viel Verlust wäre bei einem Investment in DENTSPLY SIRONA von vor 5 Jahren angefallen (finanzen.at) | |
07.11.24 |
Zuversicht in New York: Schlussendlich Gewinne im NASDAQ Composite (finanzen.at) | |
07.11.24 |
Handel in New York: Anleger lassen S&P 500 zum Ende des Donnerstagshandels steigen (finanzen.at) | |
07.11.24 |
S&P 500-Handel aktuell: S&P 500 steigt nachmittags (finanzen.at) | |
07.11.24 |
Aufschläge in New York: NASDAQ Composite am Nachmittag im Aufwind (finanzen.at) | |
07.11.24 |
Gewinne in New York: NASDAQ Composite am Donnerstagmittag freundlich (finanzen.at) | |
07.11.24 |
Donnerstagshandel in New York: So steht der S&P 500 mittags (finanzen.at) |
Analysen zu DENTSPLY SIRONA Incmehr Analysen
Aktien in diesem Artikel
DENTSPLY SIRONA Inc | 18,52 | 2,24% | |
Dr. Reddy's Laboratories Ltd. (Spons. ADRS) | 13,30 | -1,48% | |
Navient Corp | 14,60 | -1,35% |